Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Slides:

Advertisements

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Advertisements

Stephen W. Waldo et al. JACC 2008;51:

Median NT-proBNP levels (pg/mL) by GFR and 60-day survival

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

Dot plots of trisomic versus fetal fractions for cohorts 1 and 2

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 1. MAHALO clinical trial flowchart.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 2. Rheological characterization and hydrogel differentiation.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 2. Best model fits. Best model fits. Illustration of the best model fits for the (A) basic, (B) continuous, and (C) cluster models. See Table 1 and.

Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic.

Fig. 5. MMP-7 expression in human liver, EHBD, and gallbladder.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 1 Double-raster plot demonstrating the timing of sleep in the chronic sleep loss and control protocols Double-raster plot demonstrating the timing.

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 1. Genomic landscape of serial tumor biopsies and genomic and immune correlates of treatment response. Genomic landscape of serial tumor biopsies.

Fig. 4. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. Analysis of T cell responses.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

PAAND is driven by local inflammasome activation and IL-1β production

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 6. CXM correlates with age and growth velocity.

Fig. 5. Mapping of HBV S transcripts from HBeAg-positive and HBeAg-negative chimpanzees. Mapping of HBV S transcripts from HBeAg-positive and HBeAg-negative.

Evaluation of clinical responses after infusion of CART19 cells

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Analysis of the bacterial nidus within tissue abscesses by MALDI IMS demonstrates a paucity of calprotectin signal. Analysis of the bacterial nidus.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

Fig. 1 Anti-LtxA antibody concentrations in various patient groups.

Vaccination induces activation of cTFH cells and transient ASCs

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 4 cTFH1 cells correlate with a boosting of influenza-specific memory B cells. cTFH1 cells correlate with a boosting of influenza-specific memory B.

Chronic effect of 28-day oral administration of vehicle (n = 6–10/group) or aprocitentan 1, 10, and 100 mg/kg per day (n = 6–9/group) on mean arterial.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for patients undergoing surgical aortic valve replacement (SAVR) (A), patients undergoing.

Fig. 2. Soluble sugar and organic acid levels with different K fertilization during fruit development. Soluble sugar and organic acid levels with different.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration and 3 months of therapy: full analysis.

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis by Duncan B. Richards, Louise M. Cookson,

Fig. 3. Association between peak CTL019 expansion and response.

Presentation transcript:

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. (A and B) Serial measurements of liver stiffness using transient elastography after the start of dezamizumab infusion on day 1 in subjects with hepatic amyloidosis. Predose measurements before each dezamizumab infusion are indicated by PD. Median normal liver stiffness, 5.3 kPa (90% of individuals are <7.0 kPa). (A) Graph shows subjects with initial baseline liver stiffness ≤15kPa. Subject 007 () received sequential doses of 152, 600, and 2000 mg of dezamizumab. Subject 008 () received sequential doses of 246 and 600 mg. Subject 013 () received sequential doses of 650 and 600 mg. Subject 014 () received sequential doses of 600, 1000, and 500 mg. Subject 015 () received sequential doses of 600 and 2000 mg. (B) Graph shows subjects with initial baseline liver stiffness >15kPa. Subject 009 () received sequential doses of 637, 1000, and 2000 mg. Subject 010 () received sequential doses of 400, 1200, and 2000 mg. Subject 011 () received sequential doses of 650, 1000, and 2000 mg. Subject 016 () received sequential doses of 600, 2000, and 2000 mg. Subject 019 () received a single dose of 2000 mg. The interval between doses was variable: range, 3 to 12 months. (C) Serial measurements of the concentration of circulating NT-proBNP after dezamizumab treatment in subjects with proven cardiac amyloidosis. All available results are shown. S, value at screening before study; PD, predose value before each dezamizumab infusion; NT-proBNP, N-terminal pro–B-type natriuretic peptide. Results after first dose are shown on an expanded scale. Subject 018 (AL type) () received sequential doses of 600, 1200, and 1200 mg of dezamizumab. Subject 020 (AL) () received a single dose of 600 mg. Subject 021 (AL) () received sequential doses of 600, 1200, and 1200 mg. Subject 023 [transthyretin amyloidosis (ATTR)] () received a single dose of 1200 mg. Subject 024 (ATTR) () received a single dose of 1000 mg. Subject 025 (ATTR) () received a single dose of 600 mg. The interval between doses was variable: range, 2 to 3 months. Duncan B. Richards et al., Sci Transl Med 2018;10:eaan3128 Published by AAAS